

SAMARIUM-153 LABELLED MICROPARTICLES FOR LIVER TUMOUR TARGETED THERAPY WITH IMAGING FUNCTIONALITY

N.A.A. Hashikin¹, C.H. Yeong¹, B.J.J. Abdullah¹, K.H. Ng¹, L.Y. Chung², R. Dahalan³, and A.C. Perkins⁴

¹ Department of Biomedical Imaging and University of Malaya Research Imaging Centre, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia

² Department of Pharmacy, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia

³ Medical Technology Division, Malaysian Nuclear Agency, 43000 Kajang, Bangi, Malaysia.

⁴ Radiological and Imaging Sciences and Nottingham Digestive Diseases Biomedical Research Unit, University of Nottingham, Nottingham, NG7 2UH, United Kingdom.

Abstract— Samarium-153 (¹⁵³Sm) are widely used in radiation synovectomy and pain management for patients with bone metastases. However, its therapeutic application has not been fully explored. ¹⁵³Sm has been proven to be useful for imaging purposes. This provides a beneficial alternative for therapy with pure beta emitter especially for liver radioembolization with Yttrium-90 (⁹⁰Y). This study aimed to develop an alternative radioembolic agent using ¹⁵³Sm and biocompatible resin microparticles for liver cancer therapy. The ion-exchange resin; Amberlite IR-120 H⁺ commercially available in large beads were crushed and sieved to 20 – 40 μm and labelled with ¹⁵²SmCl₃ salt prior to neutron activation. Administered activity of 3 GBq ¹⁵³Sm was aimed based on the standard activity used by the ⁹⁰Y SIR-Spheres. 6 hours irradiation in 1.494 x 10¹² n.cm⁻².s⁻¹ flux produced 3.1 GBq.g⁻¹ immediately after activation. Characterization of the microparticles, gamma spectroscopy, and in-vitro radiolabelling studies were carried out and compared to a commercially available resin readily made in 20 – 40 μm, Fractogel EMD SO₃⁻ (S). ¹⁵³Sm-Amberlite microparticles possess a superior and suitable characteristics for liver radioembolization with added imaging capabilities.

Keywords— Samarium-153 (¹⁵³Sm), liver cancer, neutron activation, radioactive microspheres, radioembolization.

I. INTRODUCTION

Liver radioembolization is a non-physiological targeted therapy where radiolabeled embolic particles are percutaneously delivered directly to the tumour. Liver malignancies i.e. hepatocellular carcinoma (HCC) is the third most common cause of death from cancer worldwide (1). HCC is often diagnosed at the later stages when curative approaches are no longer feasible (2). Radioembolization using ⁹⁰Y-microparticles are now increasingly used as palliative treatment for HCC. This approach may prolong patients' survival and provide possibilities for curative intents by down-staging the tumours for possible resection or transplantation (3-7).

Currently two commercially available radioembolic agents; glass (TheraSphere[®], Nordion, Canada) and resin (SIR-Spheres, SIRTex, Australia) microparticles, both labelled with ⁹⁰Y. ⁹⁰Y is produced by high-purity separation from Strontium-90 (⁹⁰Sr), which is a nuclear fission product of Uranium-235 (²³⁵U) fuel in a nuclear reactor. The complexity of ⁹⁰Y production resulted in high cost ⁹⁰Y-microparticles. Since ⁹⁰Y is a pure beta emitter, the distribution of ⁹⁰Y-microparticles after each procedure is difficult to be verified. Technetium-99m macro-aggregated albumin (^{99m}Tc-MAA) has been used prior to therapy for lung shunting quantification providing brief information of source distribution within the liver and lungs. However, this pre-treatment planning method did not accurately reflect the intrahepatic distribution of ⁹⁰Y-microparticles. This is due to resolution and partitioning dissimilarities between ^{99m}Tc and ⁹⁰Y images, as a result of different physical characteristics and number of particles infused (8, 9). Bremsstrahlung imaging may be used, but with very poor spatial resolution.

Radionuclides with both therapeutic beta and diagnostic range of gamma energies would be ideal for “theranostics” (therapy plus diagnostic) treatment. Ideal therapeutic radionuclide has optimum physical half-life, suitable linear energy transfer (LET) and range in tissue, high ratio of non-penetrating to penetrating radiation, short lived or stable daughter, good and selective concentration with prolonged retention in tumour and minimum uptake by normal tissue (10). Neutron activation is preferred in radionuclide production due to wide availability of reactors and relatively simpler process. ¹⁵³Sm is potentially suitable as alternative to ⁹⁰Y. The imaging properties of ¹⁵³Sm has been proven feasible in a gastrointestinal scintigraphy by Yeong, Abdullah (11). Most important microparticles' feature is size range of 20 – 40 μm. Microparticles with resistivity to physical heat and body chemicals, near plasma density, biocompatible and easily labelled with radionuclides are highly preferred.

II. MATERIALS & METHODS

A. Preparation of ^{152}Sm -labelled microparticles

A commercially available ion-exchange resin; Amberlite IR-120 H^+ (620 – 830 μm) was obtained from Fluka GmbH (Buchs, Switzerland). Samarium (III) chloride hexahydrate ($^{152}\text{SmCl}_3 \cdot 6\text{H}_2\text{O}$) with assay purity $\geq 99\%$ was obtained from Aldrich Chemical Co. (Wisconsin, USA). The Amberlite IR-120 resin was oven dried at 70°C for 12 h. The dried resin was ground using a grinding planetary ball mill machine (XQM-(2-6) L, ChangSha LangFeng Metallic Material Ltd., China) at 200 rpm for approximately 5 h. The resin powder was subsequently sieved using a mechanical sieve shaker (AS 200 Analytical Sieve Shaker, Retsch GmbH, Haan, Germany) attached with 20 and 40 μm wire mesh stainless steel test sieves (Endecotts Ltd., London, UK). Another commercial ion-exchange resin, Fractogel EMD SO_3^- (S) (Merck Millipore, Massachusetts, USA) suspended in 20 % ethanol and 150 mmol.l^{-1} NaCl, ready made in 20 – 40 μm was used for functional comparison. Using Büchner funnel filtration, Fractogel resin was thoroughly washed with distilled water to eliminate the ethanol and NaCl. 1 g of $\text{SmCl}_3 \cdot 6\text{H}_2\text{O}$ was dissolved in 10 ml distilled water. 5 g of washed Fractogel resin was poured into the SmCl_3 solution and stirred for 5 min to allow binding of the Sm^{3+} ions to the resin. The ^{152}Sm -Fractogel resin was washed by flushing distilled water through the resin to remove unbound Sm^{3+} ions. These steps were repeated for ^{152}Sm -Amberlite resin. Finally, both formulations were oven dried at 70°C for 12 h.

B. Characterisation of ^{152}Sm - microparticles

Fourier transform infrared (FTIR) spectroscopy (600 – 4000 cm^{-1} range) was carried out (Nicolet 6700, Thermo Fisher Scientific Inc., Massachusetts, USA) on the Amberlite resin. FTIR spectra of SmCl_3 salt, fresh Amberlite resin beads, resin after grinding and sieving, resin after labelling, and resin after 6 h neutron activation were compared. Field emission scanning electron microscopy (FESEM) and energy dispersive X-ray (EDX) spectroscopy were carried out on both ^{152}Sm -resins using a FESEM system (Quanta FEG 250, FEI, Oregon, USA). The particle density, ρ_s of both ^{152}Sm -microparticles were measured using a helium gas pycnometer (AccuPvc II 1340, Micromeritics Ins. Corp., Georgia, USA) at standard room temperature of 25°C . The ρ_s was incorporated into following equation to obtain particle concentration, PC (particles. ml^{-1}) for each ^{152}Sm -microparticles in 0.9 % saline solution:

$$\text{PC} = \frac{6\rho_f}{\pi D_p^3 \left(\rho_f + \frac{\rho_s}{c} - \rho_s \right)} \quad (1)$$

where,

- C : mass fraction (% w/w)
- D_p : mean diameter of the particles (cm)
- ρ_f : density of the solvent (g.cm^{-3})
- ρ_s : particle density (g.cm^{-3})

C. Neutron activation

Both ^{152}Sm -microparticles were neutron activated in Malaysian Nuclear Agency (MNA), Selangor, Malaysia. The TRIGA PUSPATI Reactor (RTP) (Triga Mark II, General Atomics, California, USA) is a pool type with solid enriched uranium (20 % weight, 235U). The samples were sealed in individual polyethylene vial and placed into polyethylene ampoule. Two neutron activation methods (Table 1); Pneumatic Transfer System (PTS) and Rotary Specimen Rack (RR), were studied to achieve 3 GBq of ^{153}Sm . The irradiation time, t can be estimated using the formula:

$$A_t = \sigma_{\text{act}} \varphi N (1 - e^{-\lambda t}) \quad (2)$$

where,

- A_t : activity (Bq)
- σ_{act} : thermal neutron activation cross-section (barns)
- φ : neutron flux ($\text{n.cm}^{-2}.\text{s}^{-1}$)
- N : number of parent atoms = $(m / w) \times \theta \times 6.023 \times 10^{23}$;
- m : mass of element in the sample
- w : atomic weight of element
- θ : isotopic abundance
- λ : decay constant (s^{-1}) = $0.693 / t_{1/2}$
- t : irradiation time (s)

Table 1. Neutron activation protocols to achieve ^{153}Sm activity of 3 GBq.

Method	PTS	RR
Thermal neutron flux, θ_{th} ($\text{n.cm}^{-2}.\text{s}^{-1}$)	4.813×10^{12}	1.494×10^{12}
Irradiation time	5 minutes	6 hours
Location in the reactor	Near to the core	Peripheral to the core
Sample entrance and exit	Automatic	Manual

D. Gamma spectroscopy

After 48 h of cooling, gamma spectroscopy was carried out for each sample to determine presence of long-lived radionuclide impurities. Hyper-pure germanium detector (Canberra, Meriden, USA) and gamma spectrum analysis software (GenieTM 2000 Ver. 3.2, Canberra, Meriden, USA) were used. Each sample was counted for 5 min at a distance so that detection yield do not exceed 20 %.

E. Optimum formulation and radiolabelling efficiency

1 g of $\text{SmCl}_3 \cdot 6\text{H}_2\text{O}$ was labelled to 1, 2, 3, 4, 5, and 6 g of each resin to determine optimum formulation with best labelling efficiency. All samples were activated via PTS for 5 min. Each sample was equally separated into three 10 ml test tubes followed by addition of 10 ml distilled water. The samples were mixed using a roller mixer (Movil-Rod, J.P. Selecta, Barcelona, Spain) at 50 rpm for 1 h. Next, the samples were centrifuged at 1200 rpm for 5 min. 1 ml of supernatant was pipetted from each tube and transferred into gamma assay tubes. These steps were repeated until a total of 8 ml supernatants were obtained from each sample within 48 h. All supernatant samples were assayed using gamma scintillation counter (2470 Wizard2, PerkinElmer Inc., Massachusetts, USA). All steps were repeated in human blood plasma. Labelling efficiency of each formulation was calculated using equation previously used (12):

$$\text{Retained activity (\%)} = (A_{\text{sus}} - A_{\text{sup}}) / A_{\text{sus}} \times 100 \%$$

where,

A_{sus} : Activity of suspension before supernatant extraction

A_{sup} : Activity of supernatant

III. RESULTS

In Figure 1, the functional groups ($1000 - 1200 \text{ cm}^{-1}$) of the resin were still present despite harsh physical process during sample preparation. No major differences between peaks in spectra shown in Figure 1 (b) – (e).




Figure 1. (a) $\text{SmCl}_3 \cdot 6\text{H}_2\text{O}$ salt. (b) Fresh Amberlite IR-120 H^+ beads. (c) Amberlite IR-120 H^+ ground and sieved to size 20 – 40 μm . (d) Amberlite microparticles labelled with $\text{SmCl}_3 \cdot 6\text{H}_2\text{O}$ salt. (e) ^{153}Sm -Amberlite microparticles after 6 h neutron activation.

In Figure 2 (a), ^{152}Sm -Amberlite microparticles were observed to be irregular in shapes, however the size are in the acceptable range of 20 – 40 μm . EDX spectra of both resins

showed that they comprised mostly of C, O, Sm and S. However, for ^{152}Sm -Fractogel, Cl was also found present in a significant amount (1.66 % atomic).




Figure 2. FESEM images of (a) ^{152}Sm -Amberlite and (b) ^{152}Sm -Fractogel microparticles.

The particle density of ^{152}Sm -Amberlite and ^{152}Sm -Fractogel is 2.538 ± 0.012 and $2.283 \pm 0.002 \text{ g.cm}^{-3}$ respectively. These correspond to 27.7 and 30.7 million microparticles respectively. The specific activity per 1 g of ^{153}Sm -resins immediately after 5 min activation via PTS was $0.148 \pm 0.004 \text{ GBq}$. This correspond to only 0.072 GBq after 48 h. The specific activity achieved via RR method immediately after 6 h activation was $3.104 \pm 0.029 \text{ GBq}$. The corresponded activity of 1.513 GBq after 48 h was closer to the initial target of 3 GBq. Hence, specific activity per microparticle for ^{153}Sm -Amberlite and ^{153}Sm -Fractogel were 55 Bq and 49 Bq respectively.




Figure 3. Percentage retention of ^{153}Sm in both resin suspended in distilled water (DW) and blood plasma over 48 h.

The most dominant photopeak observed in both samples was the $103.1 \pm 0.2 \text{ keV}$, associated with principle gamma energy of ^{153}Sm . In the ^{153}Sm -Fractogel samples, two other peaks were consistently observed; 1368.4 ± 0.2 and $2753.1 \pm 0.2 \text{ keV}$, associated with ^{24}Na . No significant impurities were observed in ^{153}Sm -Amberlite samples.

^{153}Sm -Amberlite shows significantly better labelling efficiency with $8.42 \pm 0.86 \%$ higher compared to ^{153}Sm -

Fractogel. The optimum formulations determined for both ^{153}Sm -Amberlite and ^{153}Sm -Fractogel was 1:3 and 1:4 respectively. ^{153}Sm -Amberlite showed better retention over 48 h in both distilled water and blood plasma (Figure 3).

IV. DISCUSSION

Ion exchange resins were chosen due to its relatively easy labelling and commercial availability. Resins are generally chemically inert hence results in minimal radionuclide leaching. Due to its insoluble characteristic, it is not absorbed by the body thus, are extremely safe to be use in medicinal products with limited side effects (13). Amberlite IR-120 H^+ was chosen due to its excellent labelling efficiency as reported in an earlier study (12).

Chlorine (Cl) in the Fractogel resin may be activated into radioactive chlorine (^{38}Cl) during neutron activation. The presence of Cl in the Fractogel resin is due to the NaCl suspension in its commercial packing. From gamma spectroscopy, only ^{24}Na we found in the samples because ^{38}Cl may already been fully decay because of its short half-life. However, if the concentration is higher, ^{38}Cl may still be present. This issue may be overcome with more thorough resin washing during preparation.

The particle densities of the ^{152}Sm -microparticles developed in this study was in between the density of the commercial SIR-Sphere (1.6 g.cm^{-3}) and TheraSphere (3.2 g.cm^{-3}) particles. Since ^{153}Sm -Amberlite are slightly dense, this resulted in lower number of microparticles per gram which eventually contribute to higher specific activity per microparticles compared to ^{153}Sm -Fractogel.

Despite being non-spherical as a result of grinding, ^{153}Sm -Amberlite possess much better functional quality in all aspects compared to ^{153}Sm -Fractogel. The labelling efficiency and retention of ^{153}Sm -Amberlite showed that shape irregularity may not be a huge problem since ^{153}Sm are still mostly intact and the capacity of binding is significantly higher than the other resin.

V. CONCLUSION

We have prepared 20 – 40 μm microparticles using ion exchange resin labelled with ^{153}Sm produced via neutron activation. It is easy to prepare and does not involve unnecessary radiation exposure during the labelling process. Amberlite IR-120 resin was chosen rather than Fractogel EMD SO^3 because of its excellent labelling efficiency with strong retention of ^{153}Sm tested over 48 h, no radioactive impurities produced from neutron activation, and lower production cost. ^{153}Sm -microparticles has the potential to be an optimal option as an alternative to ^{90}Y -microparticles, with added advantage of gamma radiation for imaging of source distribution. Dosimetric studies to estimate total ^{153}Sm activity needed to deliver equivalent tumour dose and therapeutic response from 3 GBq ^{90}Y shall be carried out. Further animal studies for in-vivo distribution, biochemical stability and labelling efficacy should also be carried out prior to clinical studies.

ACKNOWLEDGMENT

This study was funded by the Ministry of Science, Technology and Innovation Science Fund SF011-2014, University of Malaya Postgraduate Research Fund PG104-2013B, and University of Malaya Research Grant RG459-12HTM. The neutron activation was supported by the Malaysian Nuclear Agency. A huge appreciation to medical technology division, nuclear reactor technology division and water, waste & environment division for the technical support in carrying out the research involving the TRIGA PUSPATI reactor and guidance during neutron activation analysis. The neutron activated ^{153}Sm -microparticles has been patented on February 27th, 2014 (WO2014030993 A1).

CONFLICT OF INTEREST

The authors declare that they have no conflict of interest.

REFERENCES

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International journal of cancer Journal international du cancer. 2010;127(12):2893-917. Epub 2011/02/26.

2. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. *Journal of hepatology*. 2001;35(3):421-30. Smith J, Jones M Jr, Houghton L et al (1999) Future of health insurance. *N Engl J Med* 965:325-329 DOI 10.10007/s002149800025
3. Yu CY, Ou HY, Huang TL, Chen TY, Tsang LLC, Chen CL, et al. Hepatocellular Carcinoma Downstaging in Liver Transplantation. *Transplantation proceedings*. 2012;44(2):412-4.
4. Khalaf H, Alsuhaibani H, Al-Sugair A, Al-Mana H, Al-Mutawa A, Al-Kadhi Y, et al. Use of yttrium-90 microsphere radioembolization of hepatocellular carcinoma as downstaging and bridge before liver transplantation: a case report. *Transplant Proc*. 2010;42(3):994-8.
5. Lau W, Lai EH. Salvage Surgery Following Downstaging of Unresectable Hepatocellular Carcinoma—A Strategy to Increase Resectability. *Ann Surg Oncol*. 2007;14(12):3301-9.
6. Yao FY, Kerlan RK, Hirose R, Davern TJ, Bass NM, Feng S, et al. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: An intention-to-treat analysis. *Hepatology*. 2008;48(3):819-27.
7. Ravaoli M, Grazi GL, Piscaglia F, Trevisani F, Cescon M, Ercolani G, et al. Liver Transplantation for Hepatocellular Carcinoma: Results of Down-Staging in Patients Initially Outside the Milan Selection Criteria. *American Journal of Transplantation*. 2008;8(12):2547-57.
8. Koch W, Tatsch K. Nuclear Medicine Procedures for Treatment Evaluation. In: Bilbao J, Reiser M, editors. *Liver Radioembolization with 90Y Microspheres*: Springer Berlin Heidelberg; 2008. p. 75-91.
9. Gupta T, Virmani S, Neidt TM, Szolc-Kowalska B, Sato KT, Ryu RK, et al. MR Tracking of Iron-labeled Glass Radioembolization Microspheres during Transcatheter Delivery to Rabbit VX2 Liver Tumors: Feasibility Study. *Radiology*. 2008;249(3):845-54.
10. Qaim SM. Therapeutic radionuclides and nuclear data. *Radiochim Acta*. 2001;89:297-302.
11. Yeong CH, Abdullah BJ, Ng KH, Chung LY, Goh KL, Sarji SA, et al. Production and first use of ¹⁵³SmCl₃-ion exchange resin capsule formulation for assessing gastrointestinal motility. *Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine*. 2012;70(3):450-5. Epub 2011/12/20.
12. Yeong CH, Abdullah BJ, Ng KH, Chung LY, Goh KL, Sarji SA, et al. Neutron-activated (1)(5)(3)Sm-ion-exchange resin as a tracer for gastrointestinal scintigraphy. *Nuclear medicine communications*. 2011;32(12):1256-60. Epub 2011/09/22.
13. Elder DP. Pharmaceutical Applications of Ion-Exchange Resins. *Journal of Chemical Education*. 2005;82(4):575.

Use macro [author address] to enter the address of the corresponding author:

Author: C.H. Yeong
 Institute: Department of Biomedical Imaging and University of Malaya Research Imaging Center, Faculty of Medicine
 Street: University of Malaya, 50603
 City: Kuala Lumpur
 Country: Malaysia
 Email: chyeong@um.edu.my